Author’s response to reviews

Title: Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: A Cost-Utility Study

Authors:

Georgia Kourlaba (kurlaba@gmail.com)
Charalambos Vlachopoulos (cvlachop@otenet.gr)
John Parissis (jparissis@yahoo.com)
John Kanakakis (jkanakakis@yahoo.gr)
George Gourzoulidis (gourzoulidis.g@gmail.com)
Nikos Maniadakis (nmaniadakis@esdy.edu.gr)

Version: 1 Date: 20 Nov 2015

Author’s response to reviews:

Athens, November 20, 2015

Dear Editor in Chief,

Herewith please find the revised version of our manuscript entitled "Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: A Cost-Utility Study". All changes requested are encompassed in the Word document and a point-by-point response to reviewers’ comments and editorial requests (see below). We hope that you will find our responses and modifications to be appropriate.

We remain at your disposal for any further corrections/clarifications in our manuscript Thank you in advance.

Yours Faithfully,

Kourlaba Georgia
Research Associate-Biostatistician
The Stavros Niarchos Foundation-Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO),
National and Kapodistrian University of Athens, School of Medicine
Thivon & Papadimantopoulos, 115 27, Athens, Greece
Reviewer reports:

There are another paper recently published in Value in health Journal with the same authors and similar title (1). Authors must explain and justify if the paper adds anything at all to knowledge in the particular field.

Dual submission is a case of misconduct according to COPE (Committee on Publication Ethics) and could lead even "sanctions" for the authors.


Reply: Part of this paper has been reported in poster form in the 18th Annual European Congress organized by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Milan, Italy on 7th-11th November 2015. Hence, only the abstract (up to 280 words) was published in Value in Health journal in context of congress. Therefore dual submission does not exists.

Editorial Requests

Ethics:

If your study involves humans, human data or animals, then your article should contain an ethics statement which includes the name of the committee that approved your study.

If ethics was not required for your study, then this should be clearly stated and a rationale provided.

Reply: In methods section (page 5, lines 106-109) we referred that our study is an economic evaluation analysis and does not involve human subjects no ethics approval issues arise. Input data including human material or human data were derived from other published studies performed with the approval of an appropriate ethics committee.

Consent:

If your article is a prospective study involving human participants then your article should include a statement detailing consent for participation.
If individual clinical data is presented in your article, then you must clarify whether consent for publication of these data was obtained.

Reply: As it referred above, our study is an economic evaluation analysis and does not involve human subjects no ethics approval issues arise. Input data including human material or human data were derived from other published studies performed with the approval of an appropriate ethics committee.

Availability of supporting data:

BioMed Central strongly encourages all data sets on which the conclusions of the paper rely be either deposited in publicly available repositories (where available and appropriate) or presented in the main papers or additional supporting files, in machine-readable format whenever possible. Authors must include an Availability of Data and Materials section in their article detailing where the data supporting their findings can be found. The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript must be provided and include the corresponding database name.

Reply: No clinical/economic database were used in our study. In present economic evaluation study clinical data were extracted from the published studies, as well as the cost data were obtained from local resources such as Government Gazette and Greek Ministry of Health. Moreover in manuscript referred detail the source of clinical data (clinical inputs section , page 6, lines 132-139) and the source of cost data(costing methodology section , pages 8-10 , lines 164-230)

Authors Contributions:

Your 'Authors Contributions' section must detail the individual contribution for each individual author listed on your manuscript.

Reply: In Authors contributions section (page 19 , lines 373-376) was detail referred the contribution of each individual author listed on our manuscript. However, further information was added (page 19, line 376) in red font.